Lv42
650 积分 2024-11-08 加入
Improved Rigidin-Inspired Antiproliferative Agents with Modifications on the 7-Deazahypoxanthine C7/C8 Ring Systems
1天前
已完结
Innovative medicinal chemistry strategies for enhancing drug solubility
7天前
已完结
6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
14天前
已完结
Total Synthesis of Enlicitide Decanoate
21天前
已完结
Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies
27天前
已完结
Molecular Ring Remodeling through C–C Bond Cleavage
1个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial
1个月前
已完结
Targeting cancer with small molecule pan-KRAS degraders
1个月前
已完结
SOS1 inhibitor combinations overcome KRAS inhibitor resistance
1个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
1个月前
已完结
皖公网安备34019202002308
